Jay W. Belle Isle

Before becoming LegalReader's Editor-in-Chief, Jay W. Belle Isle worked as a freelance copywriter with clients on four continents. Jay has a degree in Business Administration from Cleary University and a Juris Doctor from Thomas M. Cooley Law School. Jay has also worked as a contracts administrator for a DOD contractor specializing in vehicle armor.

RBG’s Shout-out to the U.S. Constitution

5/22/2015 In the same week that Idiotic RFG questioned Ruth Bader Ginsburg’s faith, the Notorious RBG’s shout-out to the U.S. Constitution was a fabulously shining moment during a gay wedding she officiated. The ceremony was Sunday, May 17. It is widely known that RBG has been a staunch supporter of same-sex equality during her over

Franklin Graham Prays RBG’s ‘Eyes Would Be Opened To The Truth Of Scripture’

  5/22/2015 Loud-mouthed evangelist Franklin Graham prays RBG’s ‘Eyes would be opened to the truth of Scripture’ regarding her supportive stance on gay marriage. The wing nut doesn’t fall far from the tree, apparently. Franklin is Billy Graham’s son. Billy is a famous televangelist who, at 96, is still preaching. Ruth Bader Ginsburg (the Notorious

Zerbaxa Labels Cause Confusion Over Dosages

5/21/2015 The FDA announced yesterday that it is warning healthcare professionals of potential problems with Zerbaxa (ceftolozane and tazobactam). Apparently, the Zerbaxa labels cause confusion over dosages. The risk stems from the vial label being approved with each individual active ingredients’ strength listed (e.g. 1 g/0.5 g). The product is not dosed like that, though,

FDA Posted an Alert Regarding Hospira’s LifeCare PCA3 and PCA5 Infusion Pumps

5/21/2015 Earlier this month, the FDA posted an alert regarding Hospira’s LifeCare PCA3 and PCA5 infusion pumps. The computerized systems are used to continuously deliver anesthetic or therapeutic drugs and can be programmed remotely over a hospital’s Ethernet or wireless service. Both Hospira and the FDA learned of certain security vulnerabilities in Hospira’s PCA3 and

SGLT2 Drugs Have Negative History with FDA

  5/21/2015 Quite surprising to me, I found that SGLT2 drugs have negative history with FDA. Not surprising, especially after finding the history, is the warning FDA released earlier this week. It appears that canagliflozin, sold as Invokana, may have created problems in the clinical trials that should have prevented its release. Just as other

Tort Reform Increasing Physician Supply is a Myth

5/20/2015 Welcome to the last segment of “What a Waste Wednesday: the Tort Reform Edition! Today, we wrap up the issue with a look at the impact that tort reform was supposed to have on physician availability. Simply put, tort reform increasing physician supply is a myth. The intent was for tort reform and non-economic

Bill Levin has founded the First Cannabis Church

5/19/2015 Celebrating Indiana’s commitment to religious freedom, Bill Levin has founded the First Cannabis Church and is planning a reefer revival in early July. Levin’s plan is to hold the revival the same day the Religious Freedom Restoration Act officially begins. It’s a great test, both of Indiana’s prohibition policy and the extent of the

Treatment Regimen for SGLT2-Related Ketoacidosis

5/19/2015 Yesterday we wrote about the warning issued by the FDA regarding SGLT2 type 2 diabetes medications. Today, I want to share the treatment regimen for SGLT2-related ketoacidosis. Always consult your physician before making changes in any medication protocol. If you find yourself experiencing any of the symptoms of ketoacidosis, get to the emergency room

TPP’s Effect on Mass Torts

5/18/2015 One concern that has been mentioned in numerous circles is the TPP’s effect on mass torts (class actions). My colleague wrote an insightful piece on this issue using the Alien Tort Statute. He also addressed the issue of Monsanto doing business in Vietnam, a country its Agent Orange helped decimate during the Vietnam War.

Ketoacidosis Associated with SGLT2 Inhibitors: Testing and Symptoms

5/18/2015 As my colleague wrote today, the FDA has issued a warning involving the class of type 2 diabetes drugs known as SGLT2 (sodium-glucose cotransporter-2). The drugs have been linked to approximately 20 known cases of ketoacidosis, a life-threatening condition. This post focuses on ketoacidosis associated with SGLT2 inhibitors, as well as how to test